

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Health Technology Appraisal

Pegaptanib, ranibizumab for the treatment of Age-related macular degeneration (AMD)

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

	Proposal:	Proposal made by:	Action taken:	Response:
1.	Macular Degeneration Support, Inc. (MD Support)	Macular Degeneration Support, Inc. (MD Support)	Removed	This organisation is not UK based and does not fit the criteria for selection.
2.	Alcon Laboratories	NICE	Removed	The manufacturer of anecotave acetate (Alcon Laboratories) has advised us that they have withdrawn regulatory application. The Institute has therefore decided to remove this technology from its work programme. The appraisal of ranibizumab and pegaptanib for the treatment of age-related macular degeneration will continue as per our timelines

PM Name: Alana Miller

Date: April 2005